Therapeutic Asset Ratings

369 results matching 1 filter

129,314 assets · 8,689 sponsors · 3,127 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
hr070803 pancreatic neoplasm	Fudan University	P3	CCC (50)
Ligufalimab Pancreatic Cancer	Akeso	P3	CCC (50)
Mgnp pancreatic neoplasm	Immuneering Corporation	P3	CCC (50)
N-BUTYL CYANOACRYLATE pancreatic neoplasm	Minia University	P3	CCC (50)
qls31905 pancreatic neoplasm	Qilu Pharmaceutical Co., Ltd.	P3	CCC (50)
Rmc-6236 pancreatic neoplasm	Revolution Medicines, Inc.	P3	CCC (50)
Setidegrasib pancreatic neoplasm	Astellas Pharma Global Development, Inc.	P3	CCC (50)
Zoldonrasib pancreatic neoplasm	Revolution Medicines, Inc.	P3	CCC (50)
Botensilimab pancreatic neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (50)
Hrs-4642 pancreatic neoplasm	Ruijin Hospital	P2	CCC (50)
Rivoceranib pancreatic neoplasm	Medical College of Wisconsin	P2	CCC (50)
SX682 pancreatic neoplasm	Lei Zheng	P2	CCC (50)
TEMUTERKIB pancreatic neoplasm	The Netherlands Cancer Institute	P2	CCC (50)
Tocilizumab pancreatic neoplasm	Takeda	P2	CCC (50)
Binimetinib pancreatic neoplasm	National Cancer Center, Japan	P2	CCC (49)
Eltivutabart Pancreatic Cancer	Trishula Therapeutics, Inc.	P2	CCC (48)
gsk1120212 pancreatic neoplasm	Cancer Trials Ireland	P2	CCC (48)
Regorafenib pancreatic neoplasm	Incyte Corporation	P2	CCC (48)
Tadalafil pancreatic neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (48)
TAMOXIFEN Pancreatic Cancer	Fudan University	P2	CCC (48)
dn022150+ag　(stage ii) pancreatic neoplasm	Jiangxi Kvvit Pharmaceutical Co., Ltd.	P2/3	CCC (48)
Enzalutamide pancreatic neoplasm	Nuvation Bio Inc.	P1/2	CCC (48)
Reishi Mushroom Extract Pancreatic Cancer	Fudan University	P2/3	CCC (48)
2-CHLORO-N6-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE pancreatic neoplasm	Can-Fite BioPharma	P2	CC (46)
Agen1423 pancreatic neoplasm	Bruno Bockorny	P2	CC (46)

Showing 76 to 100 of 369 assets

PreviousPage 4 of 15Next